Canney et al.: "A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination"; although a first vaccine dose was not associated with relapse risk (hazard ratio HR

50.67; 95% confidence interval [95% CI], 0.33 to 1.36), exposure to a 2nd or 3rd dose was associated with a two-fold risk of relapse (HR52.23; 95% CI, 1.06 to 4.71). Similar across glomerular disease

SOURCE:

https://pubmed.ncbi.nlm.nih.gov/36332971/

“During 281 days of follow-up, 134 (12.1%) patients experienced a relapse. Although a first vaccine dose was not associated with relapse risk (hazard ratio [HR]50.67; 95% confidence interval [95% CI], 0.33 to 1.36), exposure to a second or third dose was associated with a two-fold risk of relapse (HR52.23; 95% CI, 1.06 to 4.71). The pattern of relative risk was similar across glomerular diseases. The absolute increase in 30-day relapse risk associated with a second or third vaccine dose varied from 1%–2% in ANCA-related glomerulonephritis, minimal change disease, membranous nephropathy, or FSGS to 3%–5% in IgA nephropathy or lupus nephritis.”